Suppr超能文献

相似文献

1
Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
Semin Immunol. 2017 Jun;31:30-36. doi: 10.1016/j.smim.2017.09.001. Epub 2017 Sep 19.
3
NK cells and Immunotherapy.
Semin Immunol. 2017 Jun;31:1-2. doi: 10.1016/j.smim.2017.09.008.
4
Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
J Immunol Res. 2018 Sep 17;2018:4054815. doi: 10.1155/2018/4054815. eCollection 2018.
5
NK cell-based immunotherapy for cancer.
Semin Immunol. 2017 Jun;31:37-54. doi: 10.1016/j.smim.2017.07.009. Epub 2017 Aug 31.
6
NK cells to cure cancer.
Semin Immunol. 2019 Feb;41:101272. doi: 10.1016/j.smim.2019.03.004. Epub 2019 May 10.
7
Targeting natural killer cells in cancer immunotherapy.
Nat Immunol. 2016 Aug 19;17(9):1025-36. doi: 10.1038/ni.3518.
8
NK cell-based cancer immunotherapy: from basic biology to clinical development.
J Hematol Oncol. 2021 Jan 6;14(1):7. doi: 10.1186/s13045-020-01014-w.
9
Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Front Immunol. 2020 Feb 21;11:275. doi: 10.3389/fimmu.2020.00275. eCollection 2020.
10
Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
Trends Immunol. 2019 Dec;40(12):1078-1081. doi: 10.1016/j.it.2019.10.004. Epub 2019 Nov 12.

引用本文的文献

1
Transcriptional signature of CD56 NK cells predicts favourable prognosis in bladder cancer.
Front Immunol. 2025 Jan 14;15:1474652. doi: 10.3389/fimmu.2024.1474652. eCollection 2024.
2
Research Progress of NK Cells in Glioblastoma Treatment.
Onco Targets Ther. 2025 Jan 18;18:87-106. doi: 10.2147/OTT.S486411. eCollection 2025.
4
Immune modulations of the tumor microenvironment in response to phototherapy.
J Innov Opt Health Sci. 2023 May;16(3). doi: 10.1142/s1793545823300070. Epub 2023 Apr 27.
5
Cholesterol-regulated cellular stiffness may enhance evasion of NK cell-mediated cytotoxicity in gastric cancer stem cells.
FEBS Open Bio. 2024 May;14(5):855-866. doi: 10.1002/2211-5463.13793. Epub 2024 Mar 17.
6
Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
Front Genet. 2022 Sep 9;13:886170. doi: 10.3389/fgene.2022.886170. eCollection 2022.
7
LINC00963 May Be Associated with a Poor Prognosis in Patients with Cervical Cancer.
Med Sci Monit. 2022 Jul 12;28:e935070. doi: 10.12659/MSM.935070.
8
Aging of the Immune System: Focus on Natural Killer Cells Phenotype and Functions.
Cells. 2022 Mar 17;11(6):1017. doi: 10.3390/cells11061017.
9
A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer.
Front Immunol. 2021 Nov 10;12:724107. doi: 10.3389/fimmu.2021.724107. eCollection 2021.
10
Could Harnessing Natural Killer Cell Activity Be a Promising Therapy for Prostate Cancer?
Crit Rev Immunol. 2021;41(2):101-106. doi: 10.1615/CritRevImmunol.2021037614.

本文引用的文献

1
Elevated mean platelet volume predicts poor prognosis in colorectal cancer.
Sci Rep. 2017 Aug 31;7(1):10261. doi: 10.1038/s41598-017-11053-y.
2
Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.
Immunogenetics. 2017 Aug;69(8-9):547-556. doi: 10.1007/s00251-017-1011-9. Epub 2017 Jul 11.
3
Missing or altered self: human NK cell receptors that recognize HLA-C.
Immunogenetics. 2017 Aug;69(8-9):567-579. doi: 10.1007/s00251-017-1001-y. Epub 2017 Jul 10.
4
Complement factor P is a ligand for the natural killer cell-activating receptor NKp46.
Sci Immunol. 2017 Apr 28;2(10). doi: 10.1126/sciimmunol.aam9628.
5
Metabolic Instruction of Immunity.
Cell. 2017 May 4;169(4):570-586. doi: 10.1016/j.cell.2017.04.004.
6
Leveraging natural killer cells for cancer immunotherapy.
Immunotherapy. 2017 May;9(6):487-497. doi: 10.2217/imt-2017-0013.
7
Platelets: much more than bricks in a breached wall.
Br J Haematol. 2017 Jul;178(2):209-219. doi: 10.1111/bjh.14653. Epub 2017 Apr 17.
8
The role of the complement system in cancer.
J Clin Invest. 2017 Mar 1;127(3):780-789. doi: 10.1172/JCI90962.
10
NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.
Oncoimmunology. 2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验